ImmunoGen banks $20M up front in Lilly antibody-drug conjugate deal

 
• By Donna Young

ImmunoGen racked up another multitarget deal involving its maytansinoid Targeted Antibody Payload (TAP) technology, this time with US drug powerhouse Lilly, which plans to use the technology to develop antibody-drug conjugate (ADC) anticancer therapeutics.

More from Anticancer

More from Therapeutic Category